New York, NY (PRWEB) August 06, 2014
The birth control resource center at DrugNews.net is alerting women who have taken the oral contraceptives Yaz or Yasmin of new information on the site. A recent report shows the maker of the drugs has settled approximately 8,900 cases alleging they caused side effects*.
DrugNews is a free online resource designed to bring the latest recalls, safety alerts, research and litigation news to those taking popular prescription drugs. Visitors can recognize potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
The resource center contains warnings from health experts such as the FDA** and British Medical Journal*** that birth controls like Yaz and Yasmin, containing drospirenone, may increase blood clot risks. The U.K.’s Medicines and Healthcare Products Regulatory Agency also recently advised certain meds like Yasmin can double the risk of blood clots****.
In the United States, a number of patients have filed a Yaz lawsuit alleging side effects, leading to consolidation of cases to a special federal court (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
DrugNews has added the most recent court records, showing 8,634 cases are still pending as of July 15th*****.
Now, the resource center has learned the maker of Yaz and Yasmin, Bayer, has spent approximately $1.8 billion to settle 8,900 Yaz lawsuits through July 9th alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*.
Lawyers are still helping those injured. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is encouraged to visit DrugNews.net or speak with a lawyer about their legal options. DrugNews only recommends lawyers who have settled hundreds of Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.
*Bayer 2014 Q2 Report, Explanatory Notes, Legal Risks, 7/30/14; Retrieved from http://www.stockholders-newsletter-q2-2014.bayer.com/en/explanatory-notes.aspx
**FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
***BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
****British Journal of Family Medicine, Feb 2014; bjfm.co.uk/content/article.aspx?id=25769806997
*****JPML, 7/15/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-July-15-2014.pdf